阿帕替尼治疗中晚期胃癌的临床疗效及预后影响因素

Clinical Efficacy of Apatinib for Advanced Gastric Cancer and Prognostic Factors

目的探讨阿帕替尼治疗中晚期胃癌的疗效及预后影响因素。方法随机选取中晚期胃癌患者90名,以随机实验原则按照2∶1分成实验组(60例)和对照组(30例)。实验组除接受基本治疗外,每天还需服用425 mg的阿帕替尼;对照组则不服用阿帕替尼,而是用安慰剂来对照,其它药物与辅助治疗与实验组相同。结果实验组客观缓解率(CR+PR)为3.33%,疾病控制率(CR+PR+SD)为46.67%;对照组疾病控制率(CR+PR+SD)为3.33%,2组疾病控制率差异有统计学意义(P<0.05)。60例实验组患者中甲胎蛋白(alpha fetal protein,AFP)阳性患者的疾病控制率为65.91%,而AFP阴性患者的则为34.09%,差异有统计学意义(P<0.05)。实验组患者的PFS中位数为3.76个月,对照组患者的PFS中位数为2.65个月,2组差异有统计学意义(P<0.05)。AFP阳性患者的PFS的中位数为2.9个月,而AFP阴性患者的则为5.7个月,二者差异有统计学意义(P<0.05)。结论阿帕替尼治疗中晚期胃癌有显著的临床疗效,尤其是对于AFP阳性患者疾病控制率作用明显。

Objective To study the clinical efficacy of apatinib for advanced gastric cancer and prognostic factors. Methods 90 patients with advanced gastric cancer,according to a random experimental principle,were divided into the experi- mental group（ 60 cases） and the control group （30 cases）, the experimental group received daily 425 mg apatinib besides basi, treatment, the control group did not receive apatinib, but received placebo,other drugs and adjuvant treatment were the same as the experimental group. Results Objective response rate（CR ＋ PR） of the experimental group was 3.33% , Disease control rate （ CR ＋ PR ＋ SD） of the experimental group was 46.67% ,disease control rate（ CR ＋ PR ＋ SD） of the control group was 3.33% disease control rate of the 2 groups were significantly different （ P 〈 0.05 ） ; in the experimental group, disease control rate of alpha fetal protein（AFP） -positive and negative patients were 65.91% and 34.09% , there had significant difference（ P 〈 0.05 ） ; medi- an progression-free survival（PFS） in the experimental group was 3.76 months, and of the control group was 2.65 months, there had significant difference（ P 〈 O. 05 ）. Median PFS of AFP-positive patients was 2.9 months, and of AFP-negative patients was 5.7 months,there had significant difference（P 〈 0.05 ）. Conclusion Apatinib for advanced gastric cancer patients has signifi- cant clinical efficacy, especially for AFP-positive patients.